278 related articles for article (PubMed ID: 36408673)
1. Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis.
Zhu Y; Liu K; Wang K; Zhu H
Cancer; 2023 Jan; 129(2):283-295. PubMed ID: 36408673
[TBL] [Abstract][Full Text] [Related]
2. Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis.
Fu Z; Liu J; Li S; Shi C; Zhang Y
EClinicalMedicine; 2023 Jan; 55():101795. PubMed ID: 36712893
[TBL] [Abstract][Full Text] [Related]
3. Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis.
Suzuki Y; Zhou S; Ota Y; Harrington M; Miyagi E; Takagi H; Kuno T; Wright JD
JNCI Cancer Spectr; 2023 Aug; 7(5):. PubMed ID: 37756687
[TBL] [Abstract][Full Text] [Related]
4. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.
Masters JC; Nickens DJ; Xuan D; Shazer RL; Amantea M
Invest New Drugs; 2018 Feb; 36(1):121-135. PubMed ID: 29027591
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials.
Fu Z; Gao C; Xie J; Zhang C; Li S; Gu M; Shi C
BMC Cancer; 2023 Oct; 23(1):960. PubMed ID: 37817092
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
Zhou X; Yao Z; Bai H; Duan J; Wang Z; Wang X; Zhang X; Xu J; Fei K; Zhang Z; Tan F; Xue Q; Gao S; Gao Y; Wang J; He J
Lancet Oncol; 2021 Sep; 22(9):1265-1274. PubMed ID: 34391508
[TBL] [Abstract][Full Text] [Related]
8. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
Parisi C; Mahjoubi L; Gazzah A; Barlesi F
Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
[TBL] [Abstract][Full Text] [Related]
9. Incidence of antibody-drug conjugate-related fatigue in patients with breast cancer: A systematic review and meta-analysis.
Zhang H; Shen G; Yang P; Li J; Li Z; Liu Z; Wang M; Zhao F; Ren D; Liu Z; Zhao J; Zhao Y
Crit Rev Oncol Hematol; 2024 Apr; 196():104292. PubMed ID: 38403093
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
[TBL] [Abstract][Full Text] [Related]
11. Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis.
Zhang L; Shen D; Yu L; Yan Y; Wasan HS; Yu J; Zhang S; Sun L
Crit Rev Oncol Hematol; 2022 Sep; 177():103758. PubMed ID: 35868498
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates and Ocular Toxicity.
Jaffry M; Choudhry H; Aftab OM; Dastjerdi MH
J Ocul Pharmacol Ther; 2023 Dec; 39(10):675-691. PubMed ID: 37615544
[TBL] [Abstract][Full Text] [Related]
13. Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis.
Li J; Shen G; Liu Z; Liu Y; Wang M; Zhao F; Ren D; Xie Q; Li Z; Liu Z; Zhao Y; Ma F; Liu X; Xu Z; Zhao J
Cancer Innov; 2023 Oct; 2(5):346-375. PubMed ID: 38090386
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
15. Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis.
Zhu Z; Shen G; Li J; Qiu T; Fang Q; Zheng Y; Xin Y; Liu Z; Zhao F; Ren D; Zhao J
Crit Rev Oncol Hematol; 2023 Apr; 184():103960. PubMed ID: 36907365
[TBL] [Abstract][Full Text] [Related]
16. Risk Minimization of Antibody-Drug Conjugates in Oncology: A Review.
Lievano FA; Scarazzini LJ; Tyczynski JE; Schubert CM; Renz CL
Drug Saf; 2021 Jul; 44(7):733-742. PubMed ID: 33988833
[TBL] [Abstract][Full Text] [Related]
17. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
18. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.
Donaghy H
MAbs; 2016; 8(4):659-71. PubMed ID: 27045800
[TBL] [Abstract][Full Text] [Related]
19. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
20. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
